data room
to request information or access to content, please contact us:
- Use the Contact Us form
- Email us at ir@ecitherapeutics.com
learn more about:
our products
Our therapeutic formulation is suitable for a variety of products, including liquid eye drops, gels, ointments, contact lenses, contoured bandages, and wound dressings. Initially, ECI is pursuing ophthalmic indications for neurotrophic keratopathy (NK) and dry eye disease (DED).
ECI’s pipeline includes indications for ophthalmic burns, epithelial defects, endothelial diseases, limb stem cell deficiency, ocular graft-versus-host disease (GvHD), corneal abrasions, and chronic wounds.
our platform
Our platform leverages growth factors derived from donated human platelet-rich plasma and proprietary hyaluronic acid (HA) or chitosan. The tissue-repairing benefits of plasma-derived products, combined with the sustained action and impact of HA or chitosan, may provide relief and long-lasting therapeutic action.
our patients
Patients who experience conditions ranging from neurotrophic keratitis (NK) to dry eye disease (DED), wounds, or burns may benefit from our fusion of plasma and HA as a forward-thinking and potent strategy to potentially address their conditions with easier access and fewer side effects.